Movement Alert｜Novavax Falls 12.68% in Regular Trading, Shares Retreat After Sanofi Partnership Surge

Market Focus10-17

On October 17, Novavax fell 12.68% in Regular Trading, trading at $11.195 per share, with turnover of $87.3049 million.

The move followed a sharp pullback after the company’s previously announced partnership with Sanofi had triggered an outsized rally, suggesting the stock was giving back part of its event-driven gains.

Under the agreement disclosed earlier, the collaboration carries potential total value of up to $1.4 billion, including a $500 million upfront payment, up to $700 million in development and regulatory milestones, and $200 million tied to sales. The companies also plan to co-commercialize a COVID-19 vaccine and develop a combined COVID-19 and influenza vaccine. While that deal had briefly sent Novavax shares sharply higher, the latest decline indicates profit-taking after the initial positive reaction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment